muscle loss on tirzepatide Does Cause Loss? Clinical Evidence and Prevention Is Tirzepatide a Game-Changer in

those in the placebo group only lost 2.4%

A randomized phase 1 safety, pharmacokinetic and pharmacodynamic study of the novel myostatin inhibitor apitegromab (SRK-015): a potential treatment for spinal muscular atrophy

If you are on 5 mg daily sublingual, the approximate injectable equivalent is 7.5 to 10 mg weekly depending on your assumed bioavailability

Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al

Antidiabetic GLP-1 receptor agonists have neuroprotective properties in experimental animal models of Alzheimers disease

If you want a pharmacylevel breakdown of how oral and injectable versions differ, see the GoodRx comparison of Rybelsus vs Ozempic